Product Description: Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells[1].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598./[2]Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42.
CAS Number: 2375952-29-5
Molecular Weight: N/A
Compound Purity: 99.90
Research Area: Infection
Solubility: 10 mM in DMSO
Target: Filovirus